Details of the Drug Combination

General Information of Drug Combination (ID: DC0YU19)

Drug Combination Name
ONC201 Plinabulin
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs ONC201   DMM5SCF Plinabulin   DMD7L48
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: DIPG25
Zero Interaction Potency (ZIP) Score: 8.949
Bliss Independence Score: 12.404
Loewe Additivity Score: 6.461
LHighest Single Agent (HSA) Score: 8.671

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ONC201
Disease Entry ICD 11 Status REF
Endometrial cancer 2C76 Phase 2 [2]
Glioma 2A00.0 Phase 2 [2]
Multiple myeloma 2A83 Phase 2 [2]
Neuroendocrine cancer 2B72.1 Phase 2 [2]
Recurring respiratory infection CA07-CA45 Phase 2 [2]
leukaemia 2A60-2B33 Phase 1/2 [2]
Lymphoma 2A80-2A86 Phase 1/2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
ONC201 Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D3 receptor (D3R) TT4C8EA DRD3_HUMAN Antagonist [2]
Dopamine receptor (DR) TTWFZ1N NOUNIPROTAC Antagonist [3]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [2]
------------------------------------------------------------------------------------
Indication(s) of Plinabulin
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Phase 3 [2]
Plinabulin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Modulator [4]
Guanine nucleotide exchange factor (GNEF) TTKIGZF EI2BA_HUMAN; EI2BB_HUMAN Stimulator [2]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31.